A new study presented at the ADA’s 85th Scientific Sessions links genetic predisposition for macronutrient preference with childhood intake of sugary drinks and fast food.
A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.
A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.